PBAC's latest decision on Ranolazine: Recommended with restriction (2018). Considered for Symptomatic treatment of stable angina pectoris in patients on maximum tolerated doses of beta-blockers or calcium channel blockers where revascularisation is not an option and haemodynamic concerns limit other anti-anginal treatment options.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
2
first 2017
Submissions
2
2017 → 2018
Eligible population
Adults with stable angina pectoris on maximum tolerated doses of a beta-blocker or calcium channel blocker in whom symptoms are not controlled satisfactorily, revascularisation is not an option, and haemodynamic concerns limit other anti-anginal treatment options.
Therapy area
Cardiovascular
Line of therapy
Later-line
Evidence base
Single-arm
Primary endpoint
Surrogate
Key trials
CARISA, Lopez-Sendon (2012)
Comparator
placebo
Economic model
CUA
ICER note
The March 2017 submission estimated an ICER of less than $15,000 per QALY. Multivariate sensitivity analyses resulted in an ICER range of $15,000–$45,000 per QALY. The minor resubmission did not present a revised model.
Submission history
Mar 2017: Recommended with restriction · Authority Required
Mar 2018: Recommended with restriction · Authority Required